Akili Interactive Labs proved last week that it could convince the Food and Drug Administration to let it market a treatment delivered through a video game. Now, the Boston-based company has a new challenge — trying to show that a prescription video game can make money.
How the game fares commercially could shape the fortunes of the emerging digital therapeutics sector, which is looking to Akili to chart a path for how to persuade doctors to prescribe software-based therapies — and how to convince insurers to pay for them.
Some observers are optimistic: In a research note last week, analysts at the investment bank Jefferies forecasted peak sales of the game at $300 million in the U.S. alone.
About the Author Reprints
